supp.ai
Discover Supplement-Drug Interactions
Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 years ago
drug:
Cabergoline
supplement:
Adrenocorticotropic Hormone
Research Papers that Mention the Interaction
“Centrally acting agents, which suppress ACTH secretion, include cabergoline , octreotide, as well as the investigational agents pasireotide, bexarotene, and lapatinib, which are being studied in patients with pituitary tumors.”
Advances in medical therapies for Cushing's syndrome.“ Low-dose cabergoline promptly suppressed both ACTH and prolactin levels within 2 weeks, with unexpected clinical and biochemical hypocortisolism requiring hydrocortisone replacement.”
“ Cabergoline and pasireotide decrease ACTH production, but are effective in only 30% and 25% of patients, respectively.”
“A few case reports suggest that pasireotide or cabergoline may control tumor size and ACTH secretion from macroadenomas.”
“Octreotide (a sst(2) preferring analog) and cabergoline (D(2) agonist) both decreased the ACTH levels in the cultured tumor cells of patient 1.”
“Significant in vitro inhibition of ACTH secretion was found in 100% of D(2)-positive cases, but not in 100% of D(2)-negative cases by either bromocriptine or cabergoline.”
Help us improve supp.ai, we'd love to hear your feedback: Submit Feedback